Metrochem API Private Limited Metrochem API Private Limited

X

Find Sns-032 manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

0

Listed Suppliers

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Sns-032
Also known as: Sns-032, 345627-80-7, Bms-387032, Sns 032, Bms 387032, N-(5-(((5-(tert-butyl)oxazol-2-yl)methyl)thio)thiazol-2-yl)piperidine-4-carboxamide
Molecular Formula
C17H24N4O2S2
Molecular Weight
380.5  g/mol
InChI Key
OUSFTKFNBAZUKL-UHFFFAOYSA-N
FDA UNII
9979I93686

CDK Inhibitor SNS-032 is a small aminothiazole molecule and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. SNS-032 binds to and prevents the phosphorylation of cyclin-dependent kinases, especially CDK2, 7, and 9 that regulate cell cycle progression. Inhibition of CDKs leads to cell cycle arrest and induces apoptosis. As a result, this agent causes cytotoxicity and prevents further tumor cell growth.
1 2D Structure

Sns-032

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide
2.1.2 InChI
InChI=1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)
2.1.3 InChI Key
OUSFTKFNBAZUKL-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)(C)C1=CN=C(O1)CSC2=CN=C(S2)NC(=O)C3CCNCC3
2.2 Other Identifiers
2.2.1 UNII
9979I93686
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bms 387032

2. Bms-387032

3. Bms387032

4. Sns 032

5. Sns-032

2.3.2 Depositor-Supplied Synonyms

1. Sns-032

2. 345627-80-7

3. Bms-387032

4. Sns 032

5. Bms 387032

6. N-(5-(((5-(tert-butyl)oxazol-2-yl)methyl)thio)thiazol-2-yl)piperidine-4-carboxamide

7. N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide

8. Sns-032 (bms-387032)

9. Bms387032

10. Sns032

11. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide

12. Sns-032 (hydrochloride)

13. N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)piperidine-4-carboxamide

14. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide

15. Chembl296468

16. 345627-80-7 (free Base)

17. 4-piperidinecarboxamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-

18. 9979i93686

19. Bms-387072

20. N-(5-((5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl)-1,3-thiazol-2-yl)piperidine-4-carboxamide

21. Unii-9979i93686

22. Kinome_3820

23. Mls006011029

24. Schembl187401

25. Bdbm5931

26. Gtpl5670

27. Sns 032 [who-dd]

28. Chebi:91399

29. Cid_3025986

30. Amy2872

31. Dtxsid50188100

32. Ex-a054

33. Bcpp000066

34. Hms3295g09

35. Hms3654g10

36. Act06674

37. Bcp01951

38. Zinc3816409

39. Mfcd09833875

40. Nsc767048

41. Nsc799362

42. S1145

43. Akos015898717

44. Ccg-264835

45. Db05969

46. Nsc-767048

47. Nsc-799362

48. Sb16651

49. N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-peridinecarboxamide

50. Compound 21 [pmid: 15027863]

51. Ncgc00263167-01

52. Ncgc00263167-02

53. Ac-26846

54. As-35116

55. Hy-10008

56. Smr004702824

57. Sns-032(bms-387032)

58. Sns-032 - Bms-387032

59. A6078

60. Ft-0674612

61. Sw219478-1

62. A20554

63. 627b807

64. J-019645

65. J-523350

66. Brd-k43389698-001-01-6

67. Q27075347

68. N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)piperidine-4-carboxamide;sns-032

69. 56h

70. N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-peridinecarboxam

71. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]-thio]-2-thiazolyl]-4-piperidinecarboxamide

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 380.5 g/mol
Molecular Formula C17H24N4O2S2
XLogP33
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count7
Rotatable Bond Count6
Exact Mass380.13406837 g/mol
Monoisotopic Mass380.13406837 g/mol
Topological Polar Surface Area134 Ų
Heavy Atom Count25
Formal Charge0
Complexity454
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in cancer/tumors (unspecified), leukemia (unspecified), lymphoma (unspecified), multiple myeloma, and solid tumors.


5 Pharmacology and Biochemistry
5.1 Mechanism of Action

SNS-032 is a potent and selective inhibitor of CDKs 2, 7 and 9, which are critical in the communication and relay of signals to promote cellular growth and function. CDK2 is involved in cellular proliferation by regulating the initiation of and progression through the DNA-synthesis phase of the cell cycle. CDK7 and CDK9 are involved in transcriptional regulation of certain proteins involved in cell survival. Inappropriate activity by these CDKs can lead to unregulated proliferation, avoidance of apoptosis and increased cell survival, all of which are hallmarks of cancer. By selectively targeting these CDKs, SNS-032 may halt both aberrant cell proliferation and induce apoptosis.


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY